Enliven Therapeutics (NASDAQ:ELVN) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Enliven Therapeutics (NASDAQ:ELVN) announced its earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07, Zacks reports.

Enliven Therapeutics Stock Down 3.5 %

ELVN traded down $0.73 during trading on Thursday, reaching $20.29. 141,655 shares of the company were exchanged, compared to its average volume of 231,401. The company’s 50-day moving average is $21.73 and its two-hundred day moving average is $23.84. The company has a market cap of $991.35 million, a price-to-earnings ratio of -10.68 and a beta of 1.04. Enliven Therapeutics has a 12-month low of $10.90 and a 12-month high of $30.03.

Insider Buying and Selling

In other news, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48. Following the sale, the chief operating officer now owns 323,310 shares in the company, valued at approximately $6,931,766.40. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 1,000 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00. Following the sale, the chief financial officer now owns 13,000 shares in the company, valued at approximately $325,520. This trade represents a 7.14 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,784 shares of company stock valued at $1,092,375. Corporate insiders own 29.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Robert W. Baird increased their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.